Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab

NCT01543204 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01543204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Terminated
Start date
February 1, 2012
Completion date
May 29, 2015
Enrollment
64 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis